A Study to Evaluate the Efficacy and Safety of Gemigliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Control With Dapagliflozin and Metformin (SOLUTION Study)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 315 participants.
Also called NCT03842267
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 315 participants
- Sponsor
- LG Chem
- Registry
-
NCT03842267
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- South Korea
- Registry status
- Completed
Technical summary
Registry record NCT03842267. Randomized; double masking; primary purpose treatment. Start 2019-05-13 (actual); primary completion 2021-05-20 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Evaluate the Efficacy and Safety of Gemigliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Control With Dapagliflozin and Metformin (SOLUTION Study)
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Gemigliptin 50mg
- Intervention (Drug)
- Gemigliptin Placebo
- Lead sponsor
- LG Chem
Record details
- Record id
cardio:ct-nct03842267- Content hash
bff0bbf0e2dc61a10f3d2b6d5538ad9b8ae65e0fb797e91c3626735772d54cd5